Type 2 diabetes mellitus as a possible risk factor for myasthenia gravis: a case–control study
暂无分享,去创建一个
Y. Liu | Yafei Liu | Peng Zhang | Heng Li | R. Duan | Cong-Cong Wang | T. Du | Bing Yang | Yudong Liu | Xiao-Li Li | Chun-Lin Yang | Fang Tang
[1] Y. Liu,et al. Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. , 2022, Clinical immunology.
[2] C. Piperi,et al. Unravelling the role of Receptor for advanced glycation end products (RAGE) and its ligands in Myasthenia Gravis. , 2020, ACS chemical neuroscience.
[3] S. Luo,et al. HLA in myasthenia gravis: From superficial correlation to underlying mechanism. , 2019, Autoimmunity reviews.
[4] Antonios G. Mikos,et al. Microfluidic devices for disease modeling in muscle tissue. , 2019, Biomaterials.
[5] Zhongjun Yan,et al. Clinical differences of early and late-onset myasthenia gravis in 985 patients , 2018, Neurological research.
[6] Jong Seong Roh,et al. Damage-Associated Molecular Patterns in Inflammatory Diseases , 2018, Immune network.
[7] R. Ruff,et al. Nature and Action of Antibodies in Myasthenia Gravis. , 2018, Neurologic clinics.
[8] M. Pasnoor,et al. Diagnosis of Myasthenia Gravis. , 2018, Neurologic clinics.
[9] Yichong Li,et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013 , 2017, JAMA.
[10] F. Zouaidia,et al. Expression of receptor for advanced glycation end-products (RAGE) in thymus from myasthenia patients. , 2017, Revue neurologique.
[11] N. Gilhus,et al. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients , 2016, Journal of Neuroimmunology.
[12] Francesca Aloisi,et al. Sex-based differences in autoimmune diseases. , 2016, Annali dell'Istituto superiore di sanita.
[13] K. Kondo,et al. Late-onset myasthenia gravis is predisposed to become generalized in the elderly , 2016, eNeurologicalSci.
[14] H. Chiu,et al. Risk of diabetes mellitus among patients with myasthenia gravis , 2015, Acta neurologica Scandinavica.
[15] Jacqueline A Palace,et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. , 2015, JAMA neurology.
[16] R. Lewis. Myasthenia gravis: New therapeutic approaches based on pathophysiology , 2013, Journal of the Neurological Sciences.
[17] Jiang He,et al. Prevalence and control of diabetes in Chinese adults. , 2013, JAMA.
[18] B. Shi,et al. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. , 2013, Metabolism: clinical and experimental.
[19] D. Lacomis,et al. Characteristics of late-onset myasthenia gravis , 2012, Journal of Neurology.
[20] V. Urbonaviciute,et al. High‐mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus , 2011, Journal of internal medicine.
[21] Hulun Li,et al. Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. , 2011, Clinical immunology.
[22] D. DeMets,et al. Statistical association and causation: contributions of different types of evidence. , 2011, JAMA.
[23] D. Sanders,et al. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.
[24] J. Aarli. Myasthenia Gravis in the Elderly , 2008, Annals of the New York Academy of Sciences.
[25] M. Zorzetto,et al. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? , 2006, Modern Pathology.
[26] T. Imaizumi,et al. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.
[27] P. Tonali,et al. Thymoma in patients with MG , 2002, Neurology.
[28] D. Lawlor,et al. The association between components of adult height and Type II diabetes and insulin resistance: British Women's Heart and Health Study , 2002, Diabetologia.
[29] P. Petrow,et al. Identification of the advanced glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.
[30] C. Hennekens,et al. Contributions of different types of evidence. , 2001 .
[31] A. B. Hill,et al. "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .
[32] B. Team. British Women's Heart and Health Study: Data and study instruments , 2008 .
[33] H. Nakazora,et al. Myasthenia gravis and diabetes mellitus: a 35-year retrospective study. , 2007, Internal medicine.